<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">bmjour</journal-id><journal-title-group><journal-title xml:lang="ru">Байкальский медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Baikal Medical Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2949-0715</issn><publisher><publisher-name>Irkutsk State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.57256/2949-0715-2024-4-40-49</article-id><article-id custom-type="elpub" pub-id-type="custom">bmjour-266</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original articles</subject></subj-group></article-categories><title-group><article-title>ВЛИЯНИЕ ПРЕПАРАТА ОМНИК НА ИНТЕНСИВНОСТЬ КЛЕТОЧНЫХ РЕАКЦИЙ В ОЧАГЕ ЭКСПЕРИМЕНТАЛЬНОГО ВОСПАЛЕНИЯ</article-title><trans-title-group xml:lang="en"><trans-title>INFLUENCE OF THE DRUG OMNIC ON THE INTENSITY OF CELLULAR REACTIONS IN THE SPOTS OF EXPERIMENTAL INFLAMMATION</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5982-3875</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семинский</surname><given-names>Игорь Жанович</given-names></name><name name-style="western" xml:lang="en"><surname>Seminsky</surname><given-names>Igor Zh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, заведующий кафедрой патологической физиологии и клинической лабораторной диагностики</p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor, Head of the Department of Pathological Physiology and Clinical Laboratory Diagnostics, Irkutsk State Medical University, Russia, 664003, Irkutsk, st. Krasnogo Vosstaniya, 1. ORCID: 0000-0002-5982-3875</p></bio><email xlink:type="simple">i.seminskiy.2016@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Серебренникова</surname><given-names>Светлана Николаевна</given-names></name><name name-style="western" xml:lang="en"><surname>Serebrennikova</surname><given-names>Svetlana N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., доцент кафедры патологической физиологии и клинической лабораторной диагностики </p></bio><bio xml:lang="en"><p>Cand. Sci. (Med.), Associate Professor, Department of Pathological Physiology and Clinical Laboratory Diagnostics, Irkutsk State Medical University, Russia, 664003, Irkutsk, st. Krasnogo Vosstaniya, 1. ORCID:0000-0003-3328-4727</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7525-2657</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ткачук</surname><given-names>Елена Анатольевна</given-names></name><name name-style="western" xml:lang="en"><surname>Tkachuk</surname><given-names>Elena A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., доцент, профессор кафедры генетики ФГБОУ ВО ИГМУ Минздрава России, Россия, 664003, г. Иркутск, ул. Красного Восстания, 1; старший научный сотрудник ФГБНУ «Научный центр проблем здоровья семьи и репродукции человека», Россия, 664003, г. Иркутск, ул. Тимирязева, 16; ведущий научный сотрудник ФГБНУ «Восточно-Сибирский институт медико-экологических исследований», Россия, 665826, г. Ангарск, микрорайон 12а, дом 3</p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), Associate Professor, Professor of the Department of Pathological Physiology and Clinical Laboratory Diagnostics, Irkutsk State Medical University, Russia, 664003, Irkutsk, st. Krasnogo Vosstaniya, 1; Senior Researcher, «Scientific Center for Family Health and Human Reproduction Problems», Russia, 664003, Irkutsk, Timiryazeva St., 16; Leading Researcher, «East Siberian Institute of Medical and Ecological Research», Russia, 665826, Angarsk, microdistrict 12a, building 3. ORCID: 0000-0001-7525-2657</p></bio><email xlink:type="simple">zdorowie38@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Васильев</surname><given-names>Юрий Васильевич</given-names></name><name name-style="western" xml:lang="en"><surname>Vasiliev</surname><given-names>Yuri V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор </p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor, Irkutsk State Medical Academy of Postgraduate Education - branch of the Federal State Budgetary Educational Institution of Higher Professional Education, Russian Medical Academy of Postgraduate Education, Russia, 664049, Irkutsk, microdistrict. Yubileiny, 100</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО Иркутский государственный медицинский университет Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Irkutsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО Иркутский государственный медицинский университет Минздрава России;&#13;
ФГБНУ «Научный центр проблем здоровья семьи и репродукции человека»;&#13;
ФГБНУ «Восточно-Сибирский институт медико-экологических исследований»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Irkutsk State Medical University;&#13;
Scientific Center for Family Health and Human Reproduction Problems;&#13;
East Siberian Institute of Medical and Ecological Research</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Иркутской государственной медицинской академии последипломного образования - филиал ФГБОУ ДПО РМАНПО Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Irkutsk State Medical Academy of Postgraduate Education - branch of the Federal State Budgetary Educational Institution of Higher Professional Education, Russian Medical Academy of Postgraduate Education</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>09</day><month>12</month><year>2024</year></pub-date><volume>3</volume><issue>4</issue><fpage>40</fpage><lpage>49</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Семинский И.Ж., Серебренникова С.Н., Ткачук Е.А., Васильев Ю.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Семинский И.Ж., Серебренникова С.Н., Ткачук Е.А., Васильев Ю.В.</copyright-holder><copyright-holder xml:lang="en">Seminsky I.Z., Serebrennikova S.N., Tkachuk E.A., Vasiliev Y.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.bmjour.ru/jour/article/view/266">https://www.bmjour.ru/jour/article/view/266</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Препарат Омник (Тамсулозин)  снижает тонус гладкой мускулатуры предстательной железы, шейки мочевого пузыря, простатической части уретры, улучшает отток мочи, уменьшает симптомы обструкции и раздражения мочевыводящих путей при ДГП. Однако данные о его противовоспалительном действии противоречивы и неконкретны.</p></sec><sec><title>Цель</title><p>Цель. Определить механизмы противовоспалительного действия препарата Омник на модели гнойного воспаления у крыс.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Исследование проведено на  50 беспородных белых крысах-самцах, распределенных на 2 серии: 1 серия – контрольная (им имплантировали под кожу бедра диффузионные камеры, заполненные водной взвесью однодневной культуры staphylococcus aureus; 2 серия – опытная (животным этой серии моделировалось гнойное воспаление аналогично контролю, но с 1 суток воспаления крысам в/м вводили 0,02 мл препарата Омник в течение 10 дней). Забор материалы проводили через 2, 3, 5, 7, 10, 15, 20, 30, 60 суток после имплантации. Материал фиксировали в 10-процентном растворе нейтрального формалина. Морфометрическими методами оценивали интенсивность воспалительной реакции вокруг камеры. В периферической зоне очага воспаления качественно оценивали состояние микрососудов, подсчитывали концентрацию тучных клеток, эозинофилов, нейтрофилов, мононуклеаров и малодифференцированных фибробластов в 1000 мкм2.</p></sec><sec><title>Результаты</title><p>Результаты. В опытной группе, получавшей препарат Омник, через 48 часов после начала воспаления вокруг стен-ки камер наблюдается клеточный вал толщиной 313,18 ± 30,19 мкм. Через 3 суток после введения камер толщина лейкоцитарного вала сохраняется и составляет 334,38 ± 25,69 мкм. Через 5 суток после начала воспаления толщи-на лейкоцитарного вала резко уменьшается по сравнению с предыдущим сроком и составляет 157,86 ± 46,08 мкм. Через 7 суток после введения камер толщина клеточного вала увеличивается до 220 ± 29,67 мкм. На 10-е сутки от начала воспаления происходит уменьшение толщины вала до 129,52 ± 21,01 мкм. На 15-е сутки воспаления толщина и состояние лейкоцитарного вала не меняются. На 20–30–60-е сутки с момента имплантации камер вокруг них наблюдались остатки лейкоцитарного вала толщиной 117,86 ± 29,6 мкм.</p></sec><sec><title>Заключение</title><p>Заключение. Влияние препарата Омник на динамику клеточных реакций в очаге воспаления  усиливает миграционные способности лейкоцитов, концентрирует фибробласты вокруг лейкоцитарного вала. При этом синтез фибробластами коллагена не соответствует толщине соединительнотканной капсулы, что нарушает процесс созревания капсулы. Предположительно действия препарата Омник связано  с влиянием препарата на тонус капилляров и венул.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. The effect of the drug Omnic (Tamsulosin) reduces the tone of the smooth muscles of the prostate gland, bladder neck, prostatic part of the urethra, improves urine flow, reduces the symptoms of obstruction and irritation of the urinary tract in benign prostatic hypertrophy. However, there are no data on its anti-inflammatory effect.</p></sec><sec><title>Objective</title><p>Objective. To determine the mechanisms of the anti-inflammatory effect of the drug Omnic on the model of purulent inflammation in rats.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study was conducted on 50 outbred white male rats divided into 2 series: Series 1 - control (they were implanted with diffusion chambers filled with an aqueous suspension of a one-day culture of staphylococcus aureus under the skin of the thigh; Series 2 - experimental (the animals of this series were modeled with purulent inflammation similar to the control, but from the 1st day of inflammation, the rats were injected intramuscularly with 0.02 ml of the Omnic preparation for 10 days). The materials were collected 2, 3, 5, 7, 10, 15, 20, 30, 60 days after implantation. The material was fixed in a 10 % solution of neutral formalin. In the peripheral zone of the inflammation focus, the state of the microvessels was qualitatively assessed, the concentration of mast cells, eosinophils, neutrophils, mononuclear cells and poorly differentiated fibroblasts was counted.</p></sec><sec><title>Results</title><p>Results. After 48 Hours after the onset of inflammation, a cellular wall with a thickness of 313.18 ± 30.19 μm is observed around the chamber wall. Three days after the introduction of the chambers, the thickness of the leukocyte wall remains the same and is 334.38 ± 25.69 μm. Five days after the onset of inflammation, the thickness of the leukocyte wall decreases sharply compared to the previous period and is 157.86 ± 46.08 μm. Seven days after the introduction of the chambers, the thickness of the cellular wall increases to 220 ± 29.67 μm. On the 10th day from the onset of inflammation, the thickness of the wall decreases to 129.52 ± 21.01 μm. On the 15th day of inflammation, the thickness and condition of the leukocyte wall do not change. On days 20-30-60 from the moment of implantation of the chambers, the remains of the leukocyte shaft with a thickness of 117.86 ± 29.6 μm were observed around them.</p></sec><sec><title>Conclusion</title><p>Conclusion. The effect of Omnic on the dynamics of cellular reactions in the inflammation focus enhances the migration capacity of leukocytes, concentrates fibroblasts around the leukocyte shaft. At the same time, the synthesis of collagen by fibroblasts does not correspond to the thickness of the connective tissue capsule, which disrupts the maturation process of the capsule. Presumably, the action of Omnic is associated with the effect of the drug on the tone of capillaries and venules</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>Омник</kwd><kwd>воспаление</kwd><kwd>противовоспалительное действие</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Omnic</kwd><kwd>inflammation</kwd><kwd>anti-inflammatory effect</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Пушкарь Д.Ю., Лоран О.Б., Раснер П.И. Терапия альфа-адреноблокаторами – метод выбора в лечении обструктивного мочеиспускания у мужчин и женщин. Урол. и андрол. 2002; 10 (61).</mixed-citation><mixed-citation xml:lang="en">Пушкарь Д.Ю., Лоран О.Б., Раснер П.И. Терапия альфа-адреноблокаторами – метод выбора в лечении обструктивного мочеиспускания у мужчин и женщин. Урол. и андрол. 2002; 10 (61).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Мазо Е.Б., Белковская М.Н. Фармакотерапия доброкачественной гиперплазии простаты. Рус. мед. журн. 2001; 9 (16–17).</mixed-citation><mixed-citation xml:lang="en">Мазо Е.Б., Белковская М.Н. Фармакотерапия доброкачественной гиперплазии простаты. Рус. мед. журн. 2001; 9 (16–17).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Регистр лекарственных средств: http://www.rlsnet.ru/registration.html.</mixed-citation><mixed-citation xml:lang="en">Регистр лекарственных средств: http://www.rlsnet.ru/registration.html.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Данилов В.В., Елисеева Е.В., Данилов В.В. / К вопросу механизма действия альфа1-адреноблокаторов // РМЖ., 2010 № 2. Т. 17. С. 109-113.</mixed-citation><mixed-citation xml:lang="en">Данилов В.В., Елисеева Е.В., Данилов В.В. / К вопросу механизма действия альфа1-адреноблокаторов // РМЖ., 2010 № 2. Т. 17. С. 109-113.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kortmann BBM, Floratos DL, Kiemeney LA et al. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials. Urology 2003 Jul;62(1):1–9 (Level 4). http://www.ncbi.nlm.nih.gov/pubmed/12837408</mixed-citation><mixed-citation xml:lang="en">Kortmann BBM, Floratos DL, Kiemeney LA et al. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials. Urology 2003 Jul;62(1):1–9 (Level 4). http://www.ncbi.nlm.nih.gov/pubmed/12837408</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hu ZW, Shi XY, Hoffman BB. Doxazosin inhibits proliferation and migration of human vascular smooth-muscle cells independent of alpha1-adrenergic receptor antagonism. J Cardiovasc Pharmacol. 1998 Jun;31(6):833-9. doi: 10.1097/00005344-199806000-00006. PMID: 9641467.</mixed-citation><mixed-citation xml:lang="en">Hu ZW, Shi XY, Hoffman BB. Doxazosin inhibits proliferation and migration of human vascular smooth-muscle cells independent of alpha1-adrenergic receptor antagonism. J Cardiovasc Pharmacol. 1998 Jun;31(6):833-9. doi: 10.1097/00005344-199806000-00006. PMID: 9641467.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson R, Webb JG, Newman WH, Wang Z. Regulation of human vascular smooth muscle cell migration by beta-adrenergic receptors. Am Surg. 2006 Jan;72(1):51-4. PMID: 16494183.</mixed-citation><mixed-citation xml:lang="en">Johnson R, Webb JG, Newman WH, Wang Z. Regulation of human vascular smooth muscle cell migration by beta-adrenergic receptors. Am Surg. 2006 Jan;72(1):51-4. PMID: 16494183.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao Q, Liu QM, Jiang RC, Chen KF, Zhu X, Ma L, Li WX, He F, Huang JJ. Piperazine-Derived α1D/1A Antagonist 1- Benzyl-N- (3-(4- (2-Methoxyphenyl) Piperazine-1-yl) Propyl) -1H- Indole-2- Carboxamide Induces Apoptosis in Benign Prostatic Hyperplasia Independently of α1-Adrenoceptor Blocking. Front Pharmacol. 2021 Jan 27;11:594038. doi: 10.3389/fphar.2020.594038. PMID: 33584271; PMCID: PMC7873900.</mixed-citation><mixed-citation xml:lang="en">Xiao Q, Liu QM, Jiang RC, Chen KF, Zhu X, Ma L, Li WX, He F, Huang JJ. Piperazine-Derived α1D/1A Antagonist 1- Benzyl-N- (3-(4- (2-Methoxyphenyl) Piperazine-1-yl) Propyl) -1H- Indole-2- Carboxamide Induces Apoptosis in Benign Prostatic Hyperplasia Independently of α1-Adrenoceptor Blocking. Front Pharmacol. 2021 Jan 27;11:594038. doi: 10.3389/fphar.2020.594038. PMID: 33584271; PMCID: PMC7873900.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Martin FM, Harris AM, Rowland RG, Conner W, Lane M, Durbin E, Baron AT, Kyprianou N. Decreased risk of bladder cancer in men treated with quinazoline-based α1-adrenoceptor antagonists. Gene Ther Mol Biol. 2008;12(2):253-258. PMID: 20717483; PMCID: PMC2921713.</mixed-citation><mixed-citation xml:lang="en">Martin FM, Harris AM, Rowland RG, Conner W, Lane M, Durbin E, Baron AT, Kyprianou N. Decreased risk of bladder cancer in men treated with quinazoline-based α1-adrenoceptor antagonists. Gene Ther Mol Biol. 2008;12(2):253-258. PMID: 20717483; PMCID: PMC2921713.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Yang X, Thomas DP, Zhang X, Culver BW, Alexander BM, Murdoch WJ, Rao MN, Tulis DA, Ren J, Sreejayan N. Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):85-90. doi: 10.1161/01.ATV.0000191635.00744.b6. Epub 2005 Oct 20. PMID: 16239599.</mixed-citation><mixed-citation xml:lang="en">Yang X, Thomas DP, Zhang X, Culver BW, Alexander BM, Murdoch WJ, Rao MN, Tulis DA, Ren J, Sreejayan N. Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):85-90. doi: 10.1161/01.ATV.0000191635.00744.b6. Epub 2005 Oct 20. PMID: 16239599.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Pukac L, Huangpu J, Karnovsky MJ. Platelet-derived growth factor-BB, insulin-like growth factor-I, and phorbol ester activate different signaling pathways for stimulation of vascular smooth muscle cell migration. Exp Cell Res. 1998 Aug 1;242(2):548-60. doi: 10.1006/excr.1998.4138. PMID: 9683541.</mixed-citation><mixed-citation xml:lang="en">Pukac L, Huangpu J, Karnovsky MJ. Platelet-derived growth factor-BB, insulin-like growth factor-I, and phorbol ester activate different signaling pathways for stimulation of vascular smooth muscle cell migration. Exp Cell Res. 1998 Aug 1;242(2):548-60. doi: 10.1006/excr.1998.4138. PMID: 9683541.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Boesch ST, Corvin S, Zhang J, Rogatsch H, Bartsch G, Klocker H. Modulation of the differentiation status of cultured prostatic smooth muscle cells by an alpha1-adrenergic receptor antagonist. Prostate. 1999 Jun 1;39(4):226-33. doi: 10.1002/(sici)1097-0045(19990601)39:4&lt;226::aid-pros2&gt;3.0.co;2-8. PMID: 10344211.</mixed-citation><mixed-citation xml:lang="en">Boesch ST, Corvin S, Zhang J, Rogatsch H, Bartsch G, Klocker H. Modulation of the differentiation status of cultured prostatic smooth muscle cells by an alpha1-adrenergic receptor antagonist. Prostate. 1999 Jun 1;39(4):226-33. doi: 10.1002/(sici)1097-0045(19990601)39:4&lt;226::aid-pros2&gt;3.0.co;2-8. PMID: 10344211.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Liu QM, Xiao Q, Zhu X, Chen KF, Liu XW, Jiang RC, Wu D, Shi JM, Dai LJ, Huang JJ. Inhibitory effect of α1D/1A antagonist 2-(1H-indol-3-yl)-N-[3-(4-(2-methoxyphenyl) piperazinyl) propyl] acetamide on estrogen/androgen-induced rat benign prostatic hyperplasia model in vivo. Eur J Pharmacol. 2020 Mar 5;870:172817. doi: 10.1016/j.ejphar.2019.172817. Epub 2019 Nov 19. PMID: 31756334.</mixed-citation><mixed-citation xml:lang="en">Liu QM, Xiao Q, Zhu X, Chen KF, Liu XW, Jiang RC, Wu D, Shi JM, Dai LJ, Huang JJ. Inhibitory effect of α1D/1A antagonist 2-(1H-indol-3-yl)-N-[3-(4-(2-methoxyphenyl) piperazinyl) propyl] acetamide on estrogen/androgen-induced rat benign prostatic hyperplasia model in vivo. Eur J Pharmacol. 2020 Mar 5;870:172817. doi: 10.1016/j.ejphar.2019.172817. Epub 2019 Nov 19. PMID: 31756334.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kappert K, Sparwel J, Sandin A, Seiler A, Siebolts U, Leppänen O, Rosenkranz S, Ostman A. Antioxidants relieve phosphatase inhibition and reduce PDGF signaling in cultured VSMCs and in restenosis. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2644-51. doi: 10.1161/01.ATV.0000246777.30819.85. Epub 2006 Sep 21. PMID: 16990553.</mixed-citation><mixed-citation xml:lang="en">Kappert K, Sparwel J, Sandin A, Seiler A, Siebolts U, Leppänen O, Rosenkranz S, Ostman A. Antioxidants relieve phosphatase inhibition and reduce PDGF signaling in cultured VSMCs and in restenosis. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2644-51. doi: 10.1161/01.ATV.0000246777.30819.85. Epub 2006 Sep 21. PMID: 16990553.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kappert K, Paulsson J, Sparwel J, Leppänen O, Hellberg C, Ostman A, Micke P. Dynamic changes in the expression of DEP-1 and other PDGF receptor-antagonizing PTPs during onset and termination of neointima formation. FASEB J. 2007 Feb;21(2):523-34. doi: 10.1096/fj.06-6219com. Epub 2006 Dec 8. PMID: 17158785.</mixed-citation><mixed-citation xml:lang="en">Kappert K, Paulsson J, Sparwel J, Leppänen O, Hellberg C, Ostman A, Micke P. Dynamic changes in the expression of DEP-1 and other PDGF receptor-antagonizing PTPs during onset and termination of neointima formation. FASEB J. 2007 Feb;21(2):523-34. doi: 10.1096/fj.06-6219com. Epub 2006 Dec 8. PMID: 17158785.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
